Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | GART | P22102 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27564186 | 0.85 | CA2 (0.75) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL11001503 | 0.85 | CA2 (0.63) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL3279421 | 0.83 | CA2 (0.61) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL8379946 | 0.81 | CA2 (0.66) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL1640055 | 0.81 | CA2 (0.66) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL10934391 | 0.80 | CA2 (0.64) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL10934397 | 0.80 | CA2 (0.64) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL715646 | 0.79 | CA2 (0.67) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL97498 | 0.79 | CA2 (0.67) | CA2CA1FOLH1CA12CA9 | |
| SCHEMBL698067 | 0.79 | CA2 (0.67) | CA2CA1FOLH1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-14 | — | — | US | disclosed |
| US-9650384-B2 | Substituted pyrimidine compounds and methods of use and manufacture | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650384-B2 | Substituted pyrimidine compounds and methods of use and manufacture | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-02-11 | — | — | US | disclosed |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DHFR, FOLR1, DPYD | CA2 2113/4885CA1 2558/4885FOLH1 38/4885 |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DHFR, FOLR1, DPYD | CA2 2113/4885CA1 2558/4885FOLH1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.